RYTM insider trading — Rhythm Pharmaceuticals, Inc.
No open-market insider purchases or sales were filed for Rhythm Pharmaceuticals, Inc. (RYTM) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent RYTM insider transactions
Every Form 4 filed by Rhythm Pharmaceuticals, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Meeker David P | President and CEO | M · Option exercise · 10b5-1 | Direct | 50,000 | $6.05 | $302K | Form 4 |
| Sep 14, 2026 | Meeker David P | President and CEO | S · Sale · 10b5-1 | Direct | 50,000 | $102.67 | $5.13M | Form 4 |
| Aug 31, 2026 | Smith Hunter C | Chief Financial Officer | M · Option exercise · 10b5-1 | Direct | 57,187 | $25.79 | $1.47M | Form 4 |
| Aug 31, 2026 | Smith Hunter C | Chief Financial Officer | S · Sale · 10b5-1 | Direct | 62,774 | $105.46 | $6.62M | Form 4 |
| Aug 13, 2026 | Shulman Joseph | Chief Technical Officer | M · Option exercise · 10b5-1 | Direct | 2,024 | $6.80 | $14K | Form 4 |
| Aug 13, 2026 | Shulman Joseph | Chief Technical Officer | S · Sale · 10b5-1 | Direct | 5,079 | $119.75 | $608K | Form 4 |
| Aug 13, 2026 | Garfield Alastair | Chief Scientific Officer | S · Sale · 10b5-1 | Direct | 7,763 | $117.57 | $913K | Form 4 |
| Aug 13, 2026 | Lee Jennifer Kayden | EVP, Head of North America | M · Option exercise · 10b5-1 | Direct | 56,601 | $17.62 | $997K | Form 4 |
| Aug 13, 2026 | Lee Jennifer Kayden | EVP, Head of North America | S · Sale · 10b5-1 | Direct | 75,834 | $117.38 | $8.90M | Form 4 |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | M · Option exercise · 10b5-1 | Direct | 46,625 | $6.80 | $317K | Form 4 |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | S · Sale · 10b5-1 | Direct | 57,000 | $116.15 | $6.62M | Form 4 |
RYTM insider trading FAQ
Are insiders buying RYTM stock?
Not on the open market. In the last 90 days, Rhythm Pharmaceuticals, Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading RYTM?
No insider bought or sold on the open market in the last 90 days.
Where does RYTM insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.